Abstract
Little is known regarding the management of direct oral anticoagulants (DOACs) in patients with enzyme-inducing drugs (EID). The use of EID may lead to sub-therapeutic concentrations of DOACs and to treatment failure. Thus, many patients on EIDs cannot benefit from the advantages of DOACs. This was a retrospective study, evaluating the management of hospitalized patients with DOACs. Characteristics of hospitalized patients with a prescription for DOACs, with and without EIDs, were summarized and evaluated, and management strategies addressing the potential interaction were documented, including the use of DOAC concentration monitoring. During the period evaluated, 1596 hospitalized patients with prescriptions for DOACs were identified. Most patients received apixaban (n = 1227, 77%), followed by rivaroxaban (240, 15%), and dabigatran (129, 8%). Twenty-two patients (1.4%) had concomitant EIDs. Demographic and clinical characteristics of hospitalized patients with DOACs were similar in those receiving EID and those not. Management strategies included stopping DOAC or EID (41%), and DOAC dose increase (14%). During management of these interactions, DOAC concentrations were measured for 11 of 22 patients and were below the 5th percentile of expected concentration for six of these patients. The management of patients with DOAC concentration measurement differed significantly from those without (p = 0.005), as they were much less likely to have one of the medications stopped and more often had the DOACs’ dose increased. Among hospitalized patients with DOACs, EIDs are not rare. DOAC concentrations are often low in the presence of EIDs. DOAC concentration monitoring may be useful in settings requiring both DOAC and EIDs.
This is a preview of subscription content, log in via an institution to check access.
References
Dagan G, Perlman A, Hochberg-Klein S, Kalish Y, Muszkat M (2018) Managing direct oral anticoagulants in patients with antiepileptic medication. Can J Cardiol 34:1534-e1
King PK, Stump TA, Walkama AM, Ash BM, Bowling SM (2018) Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke. Ann Pharmacother 52:605–606
Burden T, Thompson C, Bonanos E, Medford AR (2018) Lesson of the month 2: pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. Clin Med (Northfield Il) 18:103–105
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Eur 20:1231–1242
Raval AN, Cigarroa JE, Chung MK, Diaz-sandoval LJ, Diercks D, Piccini JP et al (2017) Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 135:e604–e633
Research C for DE and Drug Development and Drug Interactions: table of substrates, inhibitors and inducers (2017) https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed 22 Dec 2018
Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Negev T, Hochberg-Klein S et al (2018) Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Heal Policy Res (in press)
Rottenstreich A, Zacks N, Kleinstern G, Raccah BH, Roth B, Da’as N et al (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 45:543–549
R Core Team (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/
Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest 151:127–138
Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol 63:321–328
Byon W, Sweeney K, Frost C, Boyd R (2017) Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacomet Syst Pharmacol 6:340–349
Leil TA, Frost C, Wang X, Pfister M, LaCreta F (2014) Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacomet Syst Pharmacol 3:e136
Douxfils J, Ageno W, Samama C-M, Lessire S, ten Cate H, Verhamme P et al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16:209–219
Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The study was approved by the institutional review board (365-15-HMO).
Rights and permissions
About this article
Cite this article
Perlman, A., Hochberg-Klein, S., Choshen Cohen, L. et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis 47, 590–595 (2019). https://doi.org/10.1007/s11239-018-01804-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-018-01804-7